Peterlabs Holdings BhdXKLS:0171 47 ROC (Joel Greenblatt) % is -9.73% as of Jun. 2025. GuruFocus rates XKLS:0171 with a GF Score™ of 47/100. Among 983 Drug Manufacturers companies, Peterlabs Holdings Bhd ranks worse than 65.01% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Peterlabs Holdings Bhd's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was -9.73%.
The historical rank and industry rank for Peterlabs Holdings Bhd's ROC (Joel Greenblatt) % or its related term are showing as below:
XKLS:0171's ROC (Joel Greenblatt) % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 11.46 * Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
Peterlabs Holdings Bhd's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
Peterlabs Holdings Bhd (XKLS:0171) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Peterlabs Holdings Bhd ROC (Joel Greenblatt) % Related Terms
Peterlabs Holdings Bhd ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Peterlabs Holdings Bhd's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Peterlabs Holdings Bhd ROC (Joel Greenblatt) % Chart
XKLS:0171 vs ZTS, UTHR, VTRS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Peterlabs Holdings Bhd's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Peterlabs Holdings Bhd ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Peterlabs Holdings Bhd's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Peterlabs Holdings Bhd's ROC (Joel Greenblatt) % falls into.
Peterlabs Holdings Bhd ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -9.73% mean?
Peterlabs Holdings Bhd (XKLS:0171) has a ROC (Joel Greenblatt) % of -9.73% as of Jun. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Peterlabs Holdings Bhd and its competitors. According to the industry distribution chart, Peterlabs Holdings Bhd ranks #639 out of 983 companies in the Drug Manufacturers industry, placing it in the top 65%.
Is Peterlabs Holdings Bhd's ROC (Joel Greenblatt) % too high?
Peterlabs Holdings Bhd's current ROC (Joel Greenblatt) % is -9.73%. Based on the distribution chart, Peterlabs Holdings Bhd ranks #639 out of 983 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Peterlabs Holdings Bhd has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Peterlabs Holdings Bhd's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Peterlabs Holdings Bhd ranks #639 out of 983 companies for ROC (Joel Greenblatt) %. This places Peterlabs Holdings Bhd in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 11.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.46, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Peterlabs Holdings Bhd and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Peterlabs Holdings Bhd's current ROC (Joel Greenblatt) % is -9.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Peterlabs Holdings Bhd stock overvalued right now?
Peterlabs Holdings Bhd (XKLS:0171) has a current ROC (Joel Greenblatt) % of -9.73%. The current ROC (Joel Greenblatt) % is -9.73%. Peterlabs Holdings Bhd's overall GF Score™ is 47/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Peterlabs Holdings Bhd (XKLS:0171), the current ROC (Joel Greenblatt) % is -9.73% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Peterlabs Holdings Bhd is engaged in the manufacturing, distribution, export, and trading of animal health and nutrition products. The Group offers biosecurity and disinfectants, compound feed supplements, feed additives, nutritional premixes, pharmaceuticals, and water-soluble supplements, as well as farm management, technical advisory services, raw material analysis, and feed formulation. Its segments are Manufacturing, which covers the manufacturing and distribution of animal health and nutrition products; Trading, which involves the trading and distribution of animal health and nutrition products and consumer goods, and contributes the majority of its revenue; and Others, which provides investment holding services. The company operates in Malaysia and internationally.
47GF Score
Get the complete analysis for XKLS:0171
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0171 has been successfully added to your 
